Molecular pathways

Targeting Tumor-infiltrating myeloid-derived suppressor cells for cancer therapy

Diletta Di Mitri, Alberto Toso, Andrea Alimonti

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Tumor-infiltrating myeloid-derived suppressor cells (MDSC) are a heterogeneous and immunosuppressive cell subset that blocks the proliferation and the activity of both T and natural killer (NK) cells and promotes tumor vasculogenesis and progression. Recent evidences demonstrate that the recruitment of MDSCs in tumors also blocks senescence induced by chemotherapy promoting chemoresistance. Hence, the need of novel therapeutic approaches that can efficiently target MDSC recruitment and function in cancer. Among them, novel combinatorial treatments of chemotherapy and immunotherapy or treatments that induce depletion of MDSCs in peripheral sites should be taken in consideration.

Original languageEnglish
Pages (from-to)3108-3112
Number of pages5
JournalClinical Cancer Research
Volume21
Issue number14
DOIs
Publication statusPublished - Jul 15 2015

Fingerprint

Cell- and Tissue-Based Therapy
Neoplasms
Drug Therapy
Natural Killer T-Cells
Immunosuppressive Agents
Immunotherapy
Therapeutics
Myeloid-Derived Suppressor Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular pathways : Targeting Tumor-infiltrating myeloid-derived suppressor cells for cancer therapy. / Di Mitri, Diletta; Toso, Alberto; Alimonti, Andrea.

In: Clinical Cancer Research, Vol. 21, No. 14, 15.07.2015, p. 3108-3112.

Research output: Contribution to journalArticle

@article{13ea3595202d495f824a83f4a7a108dc,
title = "Molecular pathways: Targeting Tumor-infiltrating myeloid-derived suppressor cells for cancer therapy",
abstract = "Tumor-infiltrating myeloid-derived suppressor cells (MDSC) are a heterogeneous and immunosuppressive cell subset that blocks the proliferation and the activity of both T and natural killer (NK) cells and promotes tumor vasculogenesis and progression. Recent evidences demonstrate that the recruitment of MDSCs in tumors also blocks senescence induced by chemotherapy promoting chemoresistance. Hence, the need of novel therapeutic approaches that can efficiently target MDSC recruitment and function in cancer. Among them, novel combinatorial treatments of chemotherapy and immunotherapy or treatments that induce depletion of MDSCs in peripheral sites should be taken in consideration.",
author = "{Di Mitri}, Diletta and Alberto Toso and Andrea Alimonti",
year = "2015",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-14-2261",
language = "English",
volume = "21",
pages = "3108--3112",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Molecular pathways

T2 - Targeting Tumor-infiltrating myeloid-derived suppressor cells for cancer therapy

AU - Di Mitri, Diletta

AU - Toso, Alberto

AU - Alimonti, Andrea

PY - 2015/7/15

Y1 - 2015/7/15

N2 - Tumor-infiltrating myeloid-derived suppressor cells (MDSC) are a heterogeneous and immunosuppressive cell subset that blocks the proliferation and the activity of both T and natural killer (NK) cells and promotes tumor vasculogenesis and progression. Recent evidences demonstrate that the recruitment of MDSCs in tumors also blocks senescence induced by chemotherapy promoting chemoresistance. Hence, the need of novel therapeutic approaches that can efficiently target MDSC recruitment and function in cancer. Among them, novel combinatorial treatments of chemotherapy and immunotherapy or treatments that induce depletion of MDSCs in peripheral sites should be taken in consideration.

AB - Tumor-infiltrating myeloid-derived suppressor cells (MDSC) are a heterogeneous and immunosuppressive cell subset that blocks the proliferation and the activity of both T and natural killer (NK) cells and promotes tumor vasculogenesis and progression. Recent evidences demonstrate that the recruitment of MDSCs in tumors also blocks senescence induced by chemotherapy promoting chemoresistance. Hence, the need of novel therapeutic approaches that can efficiently target MDSC recruitment and function in cancer. Among them, novel combinatorial treatments of chemotherapy and immunotherapy or treatments that induce depletion of MDSCs in peripheral sites should be taken in consideration.

UR - http://www.scopus.com/inward/record.url?scp=84942852950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942852950&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-2261

DO - 10.1158/1078-0432.CCR-14-2261

M3 - Article

VL - 21

SP - 3108

EP - 3112

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -